(NMR) Nomura Holdings - Ratings and Ratios
Wealth Management, Investment Management, Wholesale, Brokerage, Advisory
Dividends
| Dividend Yield | 5.13% |
| Yield on Cost 5y | 9.33% |
| Yield CAGR 5y | 1.14% |
| Payout Consistency | 85.0% |
| Payout Ratio | 47.6% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 31.6% |
| Value at Risk 5%th | 46.9% |
| Relative Tail Risk | -9.91% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.94 |
| Alpha | 17.17 |
| CAGR/Max DD | 1.34 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.411 |
| Beta | 1.128 |
| Beta Downside | 1.306 |
| Drawdowns 3y | |
|---|---|
| Max DD | 26.34% |
| Mean DD | 6.72% |
| Median DD | 6.03% |
Description: NMR Nomura Holdings October 16, 2025
Nomura Holdings, Inc. (NYSE: NMR) is a global financial services firm headquartered in Tokyo, operating through three primary segments: Wealth Management, Investment Management, and Wholesale. The Wholesale segment drives the bulk of earnings by providing institutional clients with bond, equity, FX, and derivatives trading, underwriting a broad spectrum of securities, and delivering advisory services for M&A, capital raising, and risk management. Wealth Management supplies retail and high-net-worth clients with investment products and advice, while Investment Management handles discretionary mandates, investment trusts, and fund offerings.
Key quantitative drivers (as of FY 2023) include: • Revenue of ¥1.2 trillion, with the Wholesale segment contributing roughly 70 % of total sales. • Net profit margin of 9 %, supported by a 15 % year-over-year increase in fee-based income from underwriting and advisory work. • Assets under management (AUM) of ¥12 trillion, reflecting modest growth despite a challenging low-interest-rate environment in Japan. The business is highly sensitive to market volatility, global interest-rate cycles, and the health of the Japanese yen, which affect both trading volumes and the valuation of foreign-currency-denominated assets.
If you want a deeper, data-rich assessment of Nomura’s valuation metrics and scenario analysis, a quick look at ValueRay’s analyst toolkit can help you surface the most relevant forward-looking indicators.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (370.05b TTM) > 0 and > 6% of Revenue (6% = 264.40b TTM) |
| FCFTA -0.01 (>2.0%) and ΔFCFTA -1.17pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -604.4% (prev -606.1%; Δ 1.69pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.01 (>3.0%) and CFO -678.61b <= Net Income 370.05b (YES >=105%, WARN >=100%) |
| Net Debt (9166.34b) to EBITDA (532.95b) ratio: 17.20 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.21 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (3.02b) change vs 12m ago -0.98% (target <= -2.0% for YES) |
| Gross Margin 40.96% (prev 34.97%; Δ 5.99pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 7.48% (prev 7.84%; Δ -0.36pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.30 (EBITDA TTM 532.95b / Interest Expense TTM 2601.60b) >= 6 (WARN >= 3) |
Altman Z'' -2.66
| (A) -0.44 = (Total Current Assets 7183.65b - Total Current Liabilities 33817.75b) / Total Assets 60367.70b |
| (B) 0.03 = Retained Earnings (Balance) 1975.90b / Total Assets 60367.70b |
| (C) 0.01 = EBIT TTM 782.40b / Avg Total Assets 58913.17b |
| (D) 0.03 = Book Value of Equity 1975.90b / Total Liabilities 56759.04b |
| Total Rating: -2.66 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 43.53
| 1. Piotroski 2.50pt |
| 2. FCF Yield -3.10% |
| 3. FCF Margin -19.71% |
| 4. Debt/Equity 8.99 |
| 5. Debt/Ebitda 17.20 |
| 6. ROIC - WACC (= 0.56)% |
| 7. RoE 10.57% |
| 8. Rev. Trend 81.68% |
| 9. EPS Trend 45.26% |
What is the price of NMR shares?
Over the past week, the price has changed by +1.30%, over one month by +8.06%, over three months by +7.46% and over the past year by +35.41%.
Is NMR a buy, sell or hold?
- Strong Buy: 0
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the NMR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.6 | -2.6% |
| Analysts Target Price | 7.6 | -2.6% |
| ValueRay Target Price | 9.9 | 27.8% |
NMR Fundamental Data Overview December 05, 2025
P/E Trailing = 9.9359
P/E Forward = 16.0772
P/S = 0.0115
P/B = 1.0029
P/EG = 0.851
Beta = 0.449
Revenue TTM = 4406.74b JPY
EBIT TTM = 782.40b JPY
EBITDA TTM = 532.95b JPY
Long Term Debt = 14776.43b JPY (from longTermDebt, last quarter)
Short Term Debt = 1221.74b JPY (from shortLongTermDebt, last quarter)
Debt = 31346.28b JPY (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 9166.34b JPY (from netDebt column, last quarter)
Enterprise Value = 28063.23b JPY (3548.78b + Debt 31346.28b - CCE 6831.84b)
Interest Coverage Ratio = 0.30 (Ebit TTM 782.40b / Interest Expense TTM 2601.60b)
FCF Yield = -3.10% (FCF TTM -868.58b / Enterprise Value 28063.23b)
FCF Margin = -19.71% (FCF TTM -868.58b / Revenue TTM 4406.74b)
Net Margin = 8.40% (Net Income TTM 370.05b / Revenue TTM 4406.74b)
Gross Margin = 40.96% ((Revenue TTM 4406.74b - Cost of Revenue TTM 2601.60b) / Revenue TTM)
Gross Margin QoQ = 42.03% (prev 45.25%)
Tobins Q-Ratio = 0.46 (Enterprise Value 28063.23b / Total Assets 60367.70b)
Interest Expense / Debt = 2.06% (Interest Expense 645.75b / Debt 31346.28b)
Taxrate = 29.90% (40.85b / 136.65b)
NOPAT = 548.49b (EBIT 782.40b * (1 - 29.90%))
Current Ratio = 0.21 (Total Current Assets 7183.65b / Total Current Liabilities 33817.75b)
Debt / Equity = 8.99 (Debt 31346.28b / totalStockholderEquity, last quarter 3485.28b)
Debt / EBITDA = 17.20 (Net Debt 9166.34b / EBITDA 532.95b)
Debt / FCF = -10.55 (negative FCF - burning cash) (Net Debt 9166.34b / FCF TTM -868.58b)
Total Stockholder Equity = 3500.53b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.61% (Net Income 370.05b / Total Assets 60367.70b)
RoE = 10.57% (Net Income TTM 370.05b / Total Stockholder Equity 3500.53b)
RoCE = 4.28% (EBIT 782.40b / Capital Employed (Equity 3500.53b + L.T.Debt 14776.43b))
RoIC = 2.89% (NOPAT 548.49b / Invested Capital 18971.49b)
WACC = 2.33% (E(3548.78b)/V(34895.06b) * Re(10.17%) + D(31346.28b)/V(34895.06b) * Rd(2.06%) * (1-Tc(0.30)))
Discount Rate = 10.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.90%
Fair Price DCF = unknown (Cash Flow -868.58b)
EPS Correlation: 45.26 | EPS CAGR: 4.15% | SUE: 0.00 | # QB: 0
Revenue Correlation: 81.68 | Revenue CAGR: 33.25% | SUE: 0.50 | # QB: 0
EPS current Year (2026-03-31): EPS=0.79 | Chg30d=+0.019 | Revisions Net=+1 | Growth EPS=-1.4% | Growth Revenue=+196.9%
EPS next Year (2027-03-31): EPS=0.74 | Chg30d=-0.027 | Revisions Net=-1 | Growth EPS=-6.0% | Growth Revenue=-2.8%
Additional Sources for NMR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle